"目录号: HY-14299A
GPCR/G Protein-
Indacaterol(Onbrez; Arcapta)马来酸盐是超长效β-肾上腺素受体激动剂。
Adrenergic Receptor
相关产品
Isoprenaline hydrochloride-Norepinephrine bitartrate monohydrate-(R)-(-)-Phenylephrine hydrochloride-ICI 118,551 hydrochloride-Propranolol hydrochloride-L-Epinephrine-Ivabradine hydrochloride-Clonidine hydrochloride-Salmeterol xinafoate-Phentolamine mesylate-Yohimbine Hydrochloride-Perphenazine-Silodosin-Vilanterol trifenatate-Atipamezole hydrochloride-
生物活性
Description
Indacaterol Maleate is an ultra-long-acting β-adrenoceptor agonist.Target: β-adrenoceptorIndacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human β2 adrenoceptors with pEC50 of 8.06. Indacaterol inhibits electrically induced contraction on the electrically stimulated guinea pig trachea in a concentration-dependent manner with pEC50 of 8.23. Indacaterol induces a concentration-dependent inotropic effect with maximal efficacy of 75% in the isolated guinea pig left atrium [1]. Indacaterol reverses the carbachol-induced contraction in a concentration-dependent manner with IC50 of 37 nM in human small airways. Indacaterol concentration dependently reverses the serotonin-induced contraction with IC50 of 10.5 nM in rat small airways. Indacaterol has the highest intrinsic efficacy of 53% in rat small airways and 73% in human small airways [2]. Indacaterol (6.7 μg/kg) inhibits 5-HT-induced bronchoconstriction with a maximal effect of 85% in the conscious guinea pig. Indacaterol (12.5 μg/kg) dose-dependently inhibits methacholine-induced bronchoconstriction with a maximal effect of 85% in the anesthetized rhesus monkey [1].
Clinical Trial
NCT02892019
Novartis Pharmaceuticals-Novartis
Asthma
April 18, 2017
Phase 2
NCT00636961
Novartis
Chronic Obstructive Pulmonary Disease
February 2008
Phase 2
NCT01072448
Novartis
Chronic Obstructive Pulmonary Disease
January 2010
Phase 3
NCT02418468
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
April 28, 2015
Phase 4
NCT02473237
National Institute of Respiratory Diseases, Mexico
COPD
April 2013
Phase 4
NCT02547558
Hospital Clinic of Barcelona
Chronic Obstructive Pulmonary Disease
October 2015
Phase 4
NCT00624286
Novartis
Chronic Obstructive Pulmonary Disease
February 2008
Phase 3
NCT01715311
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
November 2012
Phase 4
NCT00556673
Novartis-Merck Sharp & Dohme Corp.
Asthma
October 2007
Phase 2
NCT00876694
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
March 2009
Phase 3
NCT01272362
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
April 2010
Phase 4
NCT01068600
Novartis
Chronic Obstructive Pulmonary Disease
January 2010
Phase 3
NCT01377428
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
September 2011
Phase 4
NCT01232894
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
March 2011
Phase 3
NCT00410501
Novartis
Healthy
December 2006
Phase 1
NCT01555138
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
February 2012
Phase 4
NCT00677807
Novartis
COPD
May 2008
Phase 3
NCT01693003
Irmandade Santa Casa de Misericórdia de Porto Alegre-Novartis
Chronic Obstructive Pulmonary Disease
March 2013
Phase 4
NCT02123199
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
April 2012
NCT01156844
Novartis Pharmaceuticals-Novartis
Persistent Asthma
March 2010
Phase 2
NCT00620022
Novartis
Chronic Obstructive Pulmonary Disease
April 2008
Phase 3
NCT00615030
Novartis
Chronic Obstructive Pulmonary Disease (COPD)
January 2008
Phase 3
NCT00792805
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
November 2008
Phase 3
NCT01778062
Novartis Pharmaceuticals-Novartis
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
February 2013
Phase 3
NCT00794157
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
November 2008
Phase 3
NCT01604278
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
May 2012
Phase 3
NCT00999908
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
October 2009
Phase 3
NCT00615459
Novartis
Chronic Obstructive Pulmonary Disease (COPD)
February 2008
Phase 3
NCT00846586
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
March 2009
Phase 3
NCT00877383
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
April 2009
Phase 3
NCT00529529
Novartis Pharmaceuticals-Novartis
Asthma
September 2007
Phase 3
NCT00567996
Novartis
Chronic Obstructive Pulmonary Disease (COPD)
November 2007
Phase 3
NCT00403754
Novartis Pharmaceuticals-Novartis
Asthma
November 2006
Phase 2
NCT00927901
Novartis Pharmaceuticals-Novartis
Asthma
June 2009
Phase 2
NCT01012739
Novartis Pharmaceuticals-Novartis
Asthma
October 2009
Phase 2
NCT01377051
University of Milan-Fondazione Salvatore Maugeri
COPD-Lung Diseases-Dyspnea-Hypoxemia-Tachycardia
May 2011
Phase 4
NCT00900731
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
June 2009
Phase 3
NCT00403845
Novartis
Chronic Obstructive Pulmonary Disease
December 2006
Phase 2
NCT01543828
Novartis Pharmaceuticals-Novartis
COPD
January 2012
Phase 4
NCT00396604
Novartis
Pulmonary Disease, Chronic Obstructive-COPD-Lung Diseases, Obstructive
October 2006
Phase 2-Phase 3
NCT00403637
Novartis
Asthma
November 2006
Phase 2-Phase 3
NCT00622635
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
January 2008
Phase 3
NCT00821093
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
January 2009
Phase 3
NCT01609478
Novartis Pharmaceuticals-Novartis
Asthma
August 2012
Phase 2
NCT00393458
Novartis
Chronic Obstructive Pulmonary Disease
October 2006
Phase 3
NCT01012765
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
November 2009
Phase 3
NCT01263808
Novartis Pharmaceuticals-Novartis
Healthy Volunteers-Chronic Obstructive Pulmonary Disease
April 2008
Phase 1
NCT01959412
Novartis Pharmaceuticals-Novartis
Asthma
November 2013
Phase 2
NCT01484197
Novartis Pharmaceuticals-Novartis